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From 1998 a prospective surveillance study of Creutzfeldt-Jakob disease (CJD) has been initiated in Belgium. In 
addition to epidemiological data, information on cerebrospinal fluid biomarkers, prion protein gene and brain 
neuropathology was collected. From 1-1-1998 to 31-12-2004, 188 patients were referred to the surveillance 
system. In 85 patients a 'definite' diagnosis of sporadic CJD (sCJD) could be made, whereas 26 patients 
remained 'probable'. We further identified two unrelated patients with an E200K mutation, and two patients with 
a seven octapeptide repeat insertion in one family. In one patient a familial history was noted but genetic analysis 
was not performed. In 72 patients different final diagnoses were made, Alzheimer's disease being the most 
frequent (N = 20). The demographic parameters of the Belgian population were similar to those observed in the 
rest of Europe. We did notice a significantly increased age-specific incidence (>6/106/ year) of sCJD patients 
between 70 and 90 years old in the period 2002-2004 compared to 1998-2001 and retrospectively obtained data 
(1990-1997, p < 0.01). We undertook a detailed clinical and biochemical analysis to investigate this increase but 
could not identify any reason other than an increased vigilance for the diagnosis. In conclusion, our study 
identified that in the past sCJD may have been underestimated in patients over age 70 although these patients are 
both clinically and neurobiochemically similar to the general sCJD phenotype. 
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Introduction 
Sporadic Creutzfeldt-Jakob disease (sCJD) belongs to the group of the prion disorders or transmissible 
spongiform encephalopathies and it has always been presumed to have an incidence of 1 patient per million 
inhabitants per year [1]. The median age at death has consistently been reported to be between 60 and 65 years of 
age although a broad range, between 16 and 90 year old, has been recognised [2]. The clinical evolution of sCJD 
is variable but most commonly includes rapidly progressive dementia, motor disabilities, visual problems and 
eventually akinetic mutism, resulting in death within 1 year after onset. The definite diagnosis of CJD is based 
on the identification of the classical neuropathological triad: neuronal loss, gliosis and spongiform degeneration 
and recently of the identification prion protein deposition in the brain. A patient is diagnosed as 'possible' CJD if 
next to a fast progressive dementia with a duration of less then 2 years also 2 of the following signs can be 
identified: myoclonus, visual signs, extra-pyramidal or pyramidal signs, akinetic mutism and cerebellar signs. If 
periodic sharp wave complexes (PSWC) on the electroencephalogram (EEG) or the protein 14-3-3 test in 
cerebrospinal fluid (CSF) can be identified, patients are classified as 'probable' CJD. 
After the description of variant CJD (vCJD) and the demonstration of a link with the epidemic of bovine 
spongiform encephalopathy [3], vigilance concerning the incidence of both vCJD and sCJD was increased, 
leading to the implementation of a Belgian CJD surveillance network. 
A major development in the differential diagnosis of sCJD is the immunodetection of specific cerebrospinal fluid 
(CSF) biomarkers. Mostly the detection of the 14-3-3 protein or tau protein are used as they are reported to be 
the most sensitive and specific biomarkers for sCJD [4, 5]. In addition, decreased levels of full-length amyloid-
beta (Aβ1-42) can also be found in sCJD [6]. 
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Recently a classification of sCJD according to the three genotypes of the methionine (M)/valine (V) 
polymorphism at the codon 129 of the prion gene (PrP129) and the two types of protease resistant prion protein 
(PrPres) has been described [7]. This classification, although still under fierce debate [8-10], is now widely used 
as an added parameter in sCJD epidemiology [11]. 
In this study we report the results of the first 7 years of our prospective surveillance study. Using classical and 
recently described analyses, we compared this series with other published series including a Belgian 
retrospective study of 95 definite sCJD patients [12, 13]. 
Materials and methods 
The Belgian CJD surveillance is a collaborative study of the seven university centres of neurology/ 
neuropathology and the Institute of Public Health (IPH), which acts as the study coordinator and maintains the 
surveillance database. The university departments refer all patients which have a clinical diagnosis of 'probable' 
CJD to the IPH and eventually submit the definite, if possible the neuropathological, diagnosis to the database. 
Secondly, all Belgian 14-3-3 analyses are done in 1 centre (BBI, UA) and their database contains references to 
all patients in whom CJD was clinically suspected. This database was used as an important fail-safe to identify 
patients not investigated in the one of the university centres. All centres collected clinical data, CSF sample, 
DNA and brain tissue of patients in whom CJD was clinically suspected. In the past we had retrospectively 
collected clinical and neuropathological data on 95 definite sCJD patients [12, 13]. 
Demographic data on the Belgian population in the study period was obtained from the National Institute for 
Statistics (Belgium). 
We used a western blot to analyse the 14-3-3 protein in CSF as previously described [14]. Other biomarkers such 
as tau protein and Aβ1-42 were measured with commercial enzyme linked immuno-assays (ELISA's) 
(Innogenetics nv, Ghent, Belgium) according to the manufacturer's instructions [14, 15]. 
Brain tissue was always fixed in 10% formaldehyde and paraffin embedded sections were made in each institute 
to confirm the clinical diagnosis as previously described [13, 16]. When possible, one brain hemisphere was 
immediately frozen and stored at -80 °C. At least two independent observers assessed the neuropathological 
lesions in the 12 selected areas [17, 18]. Inter-observer variability was below 10% for all patients (data not 
shown). 
Sequencing of the prion protein gene (PRNP) and analysis of the Western blot type using a homogenate of the 
frontal cortex, were performed as previously described [19]. Patients with mutations in the PRNP were excluded 
from the analysis. 
We used non-parametric tests (Mann-Whitney U, Kruskal-Wallis) and Fisher's exact probability to compare 
frequencies. A p-value of 0.05 was considered significant. 
Results 
Demographic analysis 
From 1-1-1998 to 31-12-2004, 188 patients were referred to the Belgian surveillance system. A 'definite' 
diagnosis of sCJD could be made in 85 patients, whereas in 26 patients the diagnosis remained 'probable' as an 
autopsy was not possible. Neuropathological investigations and genetic analysis of the prion protein gene 
(PRNP) identified two unrelated patients with an E200K mutation and two patients in one family with a seven 
octapeptide repeat insertion in PRNP. In one patient a familial history was found but genetic analysis was not 
performed. In 72 patients CJD could be excluded. We observed that Alzheimer's disease (N = 20) and dementia 
with Lewy bodies (N = 12) were the most frequent alternative diagnoses. 
The probable and definite sCJD patients had a median age at death of 66 years with a standard deviation (SD) of 
10 years. The youngest patient was 32 year old at death, the oldest 88. There was a small preponderance of males 
(N = 61) over females (N = 50) although large year-to-year variations were observed (Figure 1). In our series, 
86% of patients died within the first year after disease onset. All patients lived at least 1 month after disease 
onset with a median duration of 5.7 months (SD5.6, range 1-38 months). Only small variations were found when 
we compared our series to other published series in Europe (data not shown). 
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Figure 1. The number of sCJD in Belgium since 1998. The male/female ratio strongly varies from year to year 
(maximum 3.3 (1999), minimum 0.3 (2000)) but an almost equal average ratio (1.2) was obtained. We further 
identified an increased incidence in the last 3 years (2002-2004). 
 
 
Analysis of the Belgian surveillance data indicated an average incidence of 1.6 sCJD patient/106 inhabitants/year 
with a marked increase in the last 3 years (≥1.8/106/year) of our study, but this was found not to be significant 
(Figure 1). Next, we calculated age specific incidences using the following age groups (30-39 years, 40-49 years, 
50-59 years, 60-69 years, 70-79 years, 80-89 years and above 89 years) using the data form this study and the 
average number of Belgian inhabitants in each age group for the study period (Data National Institute of 
Statistics). This calculation identified a highly increased incidence (≥6.3/106/year) between the ages of 70 and 90 
years in the last 3 years of our study. This increase was significant (p < 0.01) when compared to the incidence 
found in the first 4 years of our study period or to the Belgian sCJD patients identified retrospectively between 
1990 and 1997 (Figure 2a). This without a significant increase in the average age at death or there being a gender 
related difference. We did identify a similar significant rise if we calculated the incidence based on the total 
number of referrals to the surveillance system (Figure 2b). 
 
Figure 2. (a) Comparison of the age group specific incidence of sCJD in the 3 investigated periods. (b) 
Comparison of the age group specific incidence based upon the total number of referrals to the surveillance 
system in the 2 investigated periods. 
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To explore this finding, we first investigated whether the sCJD patients over age 70 identified between 2001 and 
2004 had a different phenotype or CSF biomarker levels compared to the other patients in our study or the 
retrospectively observed patients. The only significant difference was a decreased presence of pyramidal signs in 
the sCJD patients over 70 independent of the study period (16% vs. 44%, p = 0.04; Table 1). Also no significant 
difference was observed in the level and sensitivity of the CSF biomarkers (Table 1). 
In order to further explore these populations we analysed the neuropathological lesion profile, the PrP129 and 
the PrP western blot type in 47 sCJD patients for whom sufficient material was available (Table 2). We observed 
no meaningful difference except for, a trend towards more MM1 patients in the most recent sCJD group over 70. 
During this investigation we also compared the neuropathological lesions of individual patients with the 
characteristic lesion profile of each CJD type. We found that one MV1 and two MM1 patients had severe 
neuropathological lesions in the thalamus, neostriatum and the brainstem areas and mild lesions in the 
cerebellum resembling the neuropathological lesion profile of the MV2 class but none had 'Kuru' type plaques. 
In another MM1 patient with prolonged disease duration of 14 months, we found severe lesions and PrP morula 
type plaques in all cortical areas and the cerebellum. 
 
Table 1. Comparison of the clinical phenotype and CSF biomarker levels between the different studied periods 
and age groups. Next to the median and standard deviation of Tau and Amyloid-beta (Aβ) also the sensitivity of 
14-3-3 and tau (cutoff value 1300 pg/ml) are shown 
 90-97 1998-2001 2002-2004 
 all (N = 38) <70 years  
(N = 36) 
≥70 years  
(N = 13) 
<70 years  
(N = 33) 
≥70 years  
(N = 25) 
Dementia 100% 100% 100% 100% 100% 
Myoclonus 77% 90% 83% 81% 91% 
Visual signs 64% 42% 50% 52% 47% 
Cer 87% 90% 82% 86% 62% 
Pyr* 47% 58% 18%* 27% 16%* 
EPS 57% 40% 45% 44% 45% 
Mutism 75% 71% 80% 44% 48% 
EEG 54% 42% 58% 34% 52% 
14-3-3 100% (N = 2) 94% 90% 94% 92% 
Tau 100% 86% 90% 87% 76% 
(Pg/ml) 15870 ± 8880 9313 ± 11359 14209 ± 11337 5452 ± 4885 7239 ± 7665 
Aβ (pg/ml) 244 ± 42 282 ± 218 273 ± 212 284 ± 176 335 ± 225 
Significant differences are indicated with an asterisk (p < 0.05). (Cer: cerebellar signs, Pyr: pyramidal signs, EPS: extra-pyramidal signs, 
EEG: presence of periodic sharp wave complexes in the electro-encephalogram). 
 
Table 2. Comparison of the total sum of the three major neuropathological lesion in all examined brain areas 
between the PrP types 
Age group < 70 years ≥70 years 
CJD type MM1 
(N = 25) 
MM2  
(N = 3) 
MV1 
(N = 3) 
MV2  
(N = 4) 
VV2  
(N = 2) 
MM1 
(N = 9) 
MV2  
(N = 1) 
Spongiosis 18±2 16±3 18±1 22±3* 19±1 18±2 18 
Gliosis 15±3 16±3 17±1 20±3* 19±1* 16±3 19 
Neuronal loss 15±3 17±2 19±1 22±3* 18±1 16±1 18 
SynapticPrP + + + + + + + 
Peri-vacuolar PrP + + + + + + + 
(Kuru) plaque PrP - - Kuru Kuru + - Kuru 
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Discussion 
Our surveillance study identified an increased incidence of ≥1.8 sCJD patients per million inhabitants per year in 
the most recent years in Belgium. This increase was most pronounced in the age groups between 70 and 90 years 
old (age specific incidence ≥6.3/106/year). 
The Belgian CJD surveillance system, although voluntary, has identified one of the highest incidence figures in 
Europe. This is most likely due to a good coordination and following of the patients from clinical diagnosis to 
neuropathological confirmation. Also the existence of two independent databases contributes to smooth working 
of our system. We did agree in the beginning of the surveillance to only add probable and definite sCJD patients 
to the surveillance database because of the uncertainty of diagnosis and therefore strongly 'promote' an autopsy 
in patients suspected to have CJD (autopsy rate > 70%). 
In most European countries a similar increased incidence of sCJD was reported, especially in patients between 
age 60 and 80 (age specific incidence between 5 and 6/106/year) [20]. This finding is confirmed in our series 
although we obtained even higher incidence figures (≥7.5/106/year) in these age groups and also observed this 
increase in patients between 80 and 90 years (age specific incidence of 6.3/106/year). Most likely this increase is 
due to more accurate and vigilant surveillance of CJD but to rule out any other possibility, e.g. a link to vCJD 
and BSE, we have further exhaustively studied our series using biochemical, neuropathological and molecular 
diagnostic tools. 
The biochemical analysis of the 14-3-3 protein and tau in the CSF were shown to be sensitive markers for sCJD, 
independent of the age of the patient. Molecular diagnostic analysis showed our series to be similar to the 
previously reported sCJD populations [7, 11, 18, 21, 22]. Although molecular classification can be of use in 
surveillance projects, aberrations were detected by several authors [10, 18, 23] as well as in our series [24]. 
In conclusion, detailed analyses of our series only identified a lower rate of pyramidal signs in sCJD patients 
over age 70 whereas no further new pathological, biochemical or molecular characteristic could be identified. 
Nevertheless, our study indicates that increasing surveillance vigilance might lead to further increases in the 
incidence of sCJD in Europe as our series reveals an underestimation in patients over age 70. 
 
Acknowledgements 
The authors thank all physicians who sent us the CSF samples and clinical information of suspected CJD patients 
and control cases. 
References 
1.  Masters CL, Harris JO, Gajdusek DC, Gibbs CJ Jr., Bernoulli C, Asher DM. Creutzfeldt-Jakob disease: patterns of worldwide occurrence 
and the significance of familial and sporadic clustering. Ann Neurol 1979; 5: 177-188. 
2.  Zerr I, Poser S. Epidemiology and risk factors of transmissible spongiform encephalopathies in man. Prions 2001; 7: 93-104. 
3.  Hill AF, Desbruslais M, Joiner S, Sidle KCL, Gowland I, Collinge J, et al. The same prion strain causes vCJD and BSE. Nature 1997; 
389: 448-450. 
4.  Zerr I, Pocchiari M, Collins S, Brandel JP, Cuesta JD, Knight RSG, et al. Analysis of EEG and CSF 14-3-3 protein as aids to the 
diagnosis of Creutzfeldt-Jakob disease. Neurology 2000; 55: 811-815. 
5.  Otto M, Wiltfang J, Tumani H, Zerr I, Lantsch M, Kornhuber J, et al. Elevated levels of tau-protein in cerebrospinal fluid of patients with 
Creutzfeldt-Jakob disease. Neurosci Lett 1997; 225: 210-212. 
6.  Van Everbroeck B, Green A, Pals P, Martin JJ, Cras P. Decreased levels of amyloid-beta in cerebrospinal fluid of Creutzfeldt-Jakob 
patients. J Alz Dis 1999; 1: 343-347. 
7.  Parchi P, Giese A, Capellari S, Brown P, Schulz Schaeffer W, Windl O, et al. Classification of sporadic Creutzfeldt-Jakob disease based 
on molecular and phenotypic analysis of 300 subjects. Ann Neurol 1999; 46: 224-233. 
8.  Collinge J, Hill A, Side K. Typing prion isoforms. Nature 1997; 386: 233-234. 
9.  Parchi P, Capellari S, Chen SG, Petersen RB, Gambetti P, Kopp N, et al. Typing prion isoforms. Nature 1997; 386: 232-234. 
Published in : European Journal of Epidemiology (2006), vol. 21, pp. 443-447 
Status : Postprint (Author’s version) 
 
10.  Cardone F, Liu QG, Petraroli R, Ladogana A, D'Alessandro M, Arpino C, et al. Prion protein glycotype analysis in familial and sporadic 
Creutzfeldt-Jakob disease patients. Brain Res Bull 1999; 49: 429-433. 
11.  Alperovitch A, Zerr I, Pocchiari M, Mitrova E, Cuesta JD, Hegyi I, et al. Codon 129 prion protein genotype and sporadic Creutzfeldt-
Jakob disease. Lancet 1999; 353: 1673-1674. 
12.  Pals P, Everbroeck BV, Sciot R, Godfraind C, Rob-berecht W, Dom R, et al. A retrospective study of Creutzfeldt-Jakob disease in 
Belgium. Euro J Epidemiol 1999; 15: 517-519. 
13.  Van Everbroeck B, Pals P, Dziedzic T, Dom R, Godfraind C, Sciot R, et al. Retrospective study of Creutzfeldt-Jakob disease in 
Belgium: neuropathological findings. Acta Neuropathol 2000; 99: 358-364. 
14.  Van Everbroeck B, Quoilin S, Boons J, Martin JJ, Cras P. A prospective study of CSF markers in 250 patients with possible Creutzfeldt-
Jakob disease. J Neurol Neurosurg Psychiatry 2003; 74: 1210-1214. 
15.  Van Everbroeck B, Green A, Vanmechelen E, Vanderstichele  H,  Pals  P,   Sanchez-Valle  R,  et  al. Phosphorylated tau in cerebrospinal 
fluid as marker for Creutzfeldt-Jakob disease. J Neurol Neurosurg Psychiatry 2002; 73: 79-81. 
16.  Van Everbroeck B, Pals P, Martin JJ, Cras P. Antigen retrieval in prion protein immunohistochemistry. J Histochem Cytochem 1999; 47: 
1465-1470. 
17.  Parchi P, Castellani R, Capellari S, Ghetti B, Young K, Chen SG, et al. Molecular basis of phenotypic variability in sporadic Creutzfeldt-
Jakob disease. Ann Neurol 1996; 39: 767-778. 
18.  Hauw JJ, Sazdovitch V, Laplanche JL, Peoc' h K, Kopp N, Kemeny J, et al. Neuropathologic variants of sporadic Creutzfeldt-Jakob 
disease and codon 129 of PrP gene. Neurology 2000; 54: 1641-1646. 
19.  Van Everbroeck B, Croes EA, Pals P, Dermaut B, Jansen G, van Duijn CM, et al. Influence of the prion protein and the apolipoprotein E 
genotype on the Creutzfeldt-Jakob Disease phenotype. Neurosci Lett 2001; 313: 69-72. 
20.   Ladogana A, Puopolo M, Croes EA, Budka H, Jarius C, Collins S, et al. Mortality from Creutzfeldt-Jakob disease and related disorders 
in Europe, Australia, and Canada. Neurology 2005; 64: 1586-1591. 
21.  de Silva R, Ironside JW, McCardle L, Esmonde T, Bell J, Will R, et al. Neuropathological phenotype and 'prion protein' genotype 
correlation in sporadic Creutzfeldt-Jakob disease. Neurosci Lett 1994; 179: 50-52. 
22.  Kitamoto T, Dohura K, Muramoto T, Miyazono M, Tateishi J. The primary structure of the prion protein influences the distribution of 
abnormal prion protein in the central nervous system. Am J Pathol 1992; 141: 271-277. 
23.  Ironside JW, Head MW, Bell JE, McCardle L, Will RG. Laboratory diagnosis of variant Creutzfeldt-Jakob disease. Histopathology 
2000; 37: 1-9. 
24.  Zarranz JJ, Digon A, Atares B, Rodriguez-Martinez AB, Arce A, Carrera N, et al. Phenotypic variability in familial prion diseases due to 
the D178N mutation. J Neurol Neurosurg Psychiatry 2005; 76: 1491-1496. 
